There seem to be a lot of posts disparaging management with little or no evidence that they've done anything wrong. The main cause of the discontent appears to be the fact that it's taking so long to get product out. I've got news for you folks. That's the normal course of business for pharmaceutical and biotechnology companies. It takes time to conduct research and there are often many setbacks. There's zero evidence that there have been any intentional unjustified delays.
The other main argument seems to be that they are a pump and dump. Again, I see no evidence that this is the case. There have been no insider sales in the past six months. They seem to sell shares early in the year to meet their income needs for that year so I wouldn't be surprised to see some insider sales in 1FQ20.
Why would management want their pps to continually drift down. Yes, InMed will probably need more funding sometime in 2020 to complete clinical trials. Normally, as a company comes closer to producing revenue the share price goes up and fewer new shares need to be issued to fund the R&D. Hopefully, Biosynthesis will be generating revenue by the time new funding is needed and this will result in a higher pps. Otherwise, shareholders should be welcoming a nice pump to preserve our investment.
News 
Market Data 
Discover 
